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Abstract: The present study aimed to assess antibody seropositivity prevalence among symptomatic
individuals and individuals with a high risk of occupational exposure to SARS-CoV-2. Participants
from Chelyabinsk (Russian Federation) who were at an increased risk of exposure to SARS-CoV-2
(high-risk group, n = 1091) and participants who either had symptoms consistent with COVID-19
or were suspected to have experienced COVID-19 in the past (symptomatic group, n = 692) were
enrolled between 28 September and 30 December 2020. Blood samples were tested by enzyme-linked
immunosorbent assay D-5501 SARS-Cov-2-IgG-EIA-BEST and D-5502 SARS-Cov-2-IgM-EIA-BEST
(AO Vector-Best, Novosibirsk, Russia). The overall seropositivity rate was 28.33–28.53%. SARS-CoV-2
antibodies were detected in 17.23% (adjusted prevalence of 17.17–17.29%) of participants in the high-
risk and 45.95% (adjusted prevalence of 45.91–46.24%) in the symptomatic group. Higher IgG and
IgM titers were observed in women compared to men, as well as in participants in the symptomatic
group compared to those in the high-risk group. The results indicate that the seroprevalence among
residents in several Russian regions is low (28.38%) and inadequate to provide herd immunity. The
lower seroprevalence among participants in the high-risk group may be attributed to the enforcement
of healthcare protocols and the use of adequate personal protective equipment.
Keywords: antibody; COVID-19; focus groups; global health; high-risk groups; seroprevalence
1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly to more than
180 countries worldwide, resulting in high levels of morbidity and mortality. As of 9 May
2021, nearly 166 million COVID-19 cases and 3449 million deaths have been reported [1].
The clinical manifestations of COVID-19 can range from an asymptomatic/mild
disease to severe disease with acute respiratory tract infections. Data from the meta-analysis
suggest that the pooled prevalence of asymptomatic COVID-19 is about 48% and is higher
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in females than in males [2]. With that, because of the absence of symptoms and complaints,
asymptomatic COVID-19 carriers can escape detection from the health system and, thus,
are challenging for the implementation of preventive measures and infection control [2].
Thus, as the majority of currently available data are restricted to symptomatic patients
with laboratory-confirmed COVID-19, the extent of the pandemic may be underestimated,
and the virus may have a great potential for silent spread through the population [3,4].
Moreover, a recent meta-analysis reported a pooled ratio of serologically-detected infections
to virologically-confirmed cases of 7.7; that is, for each confirmed case of severe acute
respiratory syndrome coronavirus 2 (SARS-COV-2) infection, at least six infections remain
undetected by current surveillance systems [5].
While CDC does not recommend serology testing to diagnose the current infection [6],
its utility and importance for public health should be more emphasized in the COVID-19
pandemic [7]. As the duration of immunity to SARS-CoV-2 dictates the overall course of the
pandemic and can also affect post-pandemic dynamics [8], serological studies are urgently
needed [9]. The results of such studies can facilitate the assessment of infection spread,
infection fatality rates, level of herd immunity, and the impact of interventions [5]. Public
health decision-making would especially benefit from data pertaining to seroprevalence
among individuals in occupations with a high risk of exposure to SARS-CoV-2 due to
frequent social interactions (e.g., service-sector employees) [10].
The seroconversion of specific SARS-CoV-2 IgG/IgM antibodies can start as early
as 4 days [11], with the median time of 7–8 days [12], after the onset of illness, and
both IgG and IgM titers plateau within 6 days after seroconversion [13]. Most patients
have neutralizing titers on days 14–20 with great titer variability [14]. The duration of
the positivity rate exceeding 80% is about seven weeks for IgM and about 3–6 months
for IgG [15]. According to the current data, the prevalence and dynamic characteristics
of SARS-CoV-2 IgG/IgM antibodies are affected by age, sex, and disease severity [16];
however, the research population studied is still not comprehensive and that causes the
discrepancies in results among the studies [14].
A considerable amount of literature has been published on the impact of the pandemic
on healthcare workers [17], while the studies investigating other essential workers with
direct customer exposure are limited [18,19]. With that, the elevated risk of infection was
not limited to healthcare workers, and other high-risk occupations being affected during
the pandemic comprised almost half of local transmission and the majority of the possible
work-related cases [10,20,21].
Although the COVID-19 outbreak in Russia started later compared to many neigh-
boring European countries, Russia is currently among the six countries with the highest
number of confirmed COVID-19 cases, as of 9 May 2021 [22,23]. Limited data suggest
that the seroprevalence of SARS-CoV-2 infection in Russia was approximately 9–10% in
May–June 2020 [24], reaching 19.6–31.3% [25–27] by the end of the year. At present, there
are no data for seropositivity rates in specific cohorts, such as those with a high risk of
occupational exposure to SARS-CoV-2. Moreover, because of the high risk for infection
spread by persons with an asymptomatic form of the disease, serological studies should
include those from high-risk groups even without the symptoms.
Thus, the present pilot study aimed to assess and compare antibody seropositivity
prevalence rates among symptomatic individuals and individuals in occupations with a
high risk of exposure to SARS-CoV-2.
2. Materials and Methods
2.1. Location of the Study
Chelyabinsk is the seventh-largest city in Russia with a population of approximately
1.3 million. The city has a humid continental climate (Köppen: Dfb): the average tem-
perature in January is −14 ◦C/6.6 ◦F. and 19 ◦C/66.7 ◦F in July. The first case in the city
was registered on 21 March 2020, and 58,380 cases with 1417 deaths from COVID-19 were
reported as of 24 April 2021.
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2.2. Study Design, Population, and Sampling
In this cross-sectional study, we assessed the prevalence of SARS-CoV-2 infection via
serological testing for anti-SARS-CoV-2 antibodies. A total of 1300 persons, who were
at an increased risk of exposure to SARS-CoV-2 (i.e., healthcare workers, education staff,
and supermarket employees), were invited to participate in a free employer-sponsored
SARS-CoV-2 serology assessment between 28 September 2020 and 30 December 2020.
This study excluded patients younger than 18 years with a history of coronary heart
disease, pre-excitation syndromes, motor impairments (cerebral palsy and epilepsy), with
pacemakers, drug addicts, and dialysis patients.
One thousand and ninety-one persons were enrolled in the study and comprised
the “high-risk” group; 209 persons did not agree to participate or did not attend the
hospital for a scheduled appointment. Individuals were excluded from this group if they
reported symptoms of COVID-19 or other acute respiratory virus infections on the day of
the appointment.
Six hundred and ninety-two persons who had symptoms, reported having symptoms
consistent with COVID-19 or other acute respiratory virus infections (fever, muscle pain,
tiredness, headache, cough, sore throat, new loss of taste or smell, and a blocked nose),
were suspected to have COVID-19 infection in the past, or had contact with COVID-19
infected persons and self-reported for enrolment in the study comprised the “symptomatic/
contact group”.
2.3. Ethical Permission
The study proposal and protocol were approved by the ethics committee of the
Institute of Health “DoctorLab” (1 July 2020). Reporting was in accordance with the
Strengthening the Reporting of Observational Studies in Epidemiology guidelines. A
representative of the research team approached the individuals by phone to ask if they
would be willing to have a research coordinator speak to them about the study. If yes, the
coordinator spoke with them, described the study (risks/benefits, voluntary participation,
and procedures). Individuals were given adequate time to reflect on the information, had
any questions answered, and gave free and voluntary consent. Patient consent forms were
distributed to the participants at reception areas of the Institute of Health “DoctorLab”
(LLC “DoctorLab”).
2.4. Laboratory Tests
Peripheral blood was collected by venipuncture in BD Vacutainer® SST™ Tubes
containing spray-coated silica and a polymer gel for serum separation (BD Biosciences,
San Jose, CA, USA) and centrifuged at 1500× g for 20 min. The obtained blood serum
was used for the IgM and IgG detection on the day of venipuncture. Serum samples were
tested by enzyme-linked immunosorbent assay (ELISA) D-5501 SARS-Cov-2-IgG-EIA-
BEST and D-5502 SARS-Cov-2-IgM-EIA-BEST (AO Vector-Best, Novosibirsk, Russia). All
samples were tested in duplicate. The test was performed according to the manufacturer’s
instructions [28].
The method of determination is based on a two-stage “indirect” version of ELISA.
At the first stage of the analysis, the specific antibodies (IgG or IgM) contained in the
test samples bind to the recombinant SARS-CoV-2 antigen immobilized on the surface
of the plate wells—receptor-binding domain (RBD) of glycoprotein S (Spike, S-protein).
At the second stage, the conjugate of monoclonal antibodies to human IgG (IgM) with
horseradish peroxidase interacts with antigen–IgG (antigen–IgM) complexes. During
incubation (25 min) with a tetramethylbenzidine solution, the solution stains in the wells
contained the formed antigen–IgG-conjugate complexes. After stopping the reaction by
addition of the stop solution (1 N H2SO4), absorbance at 450 nm with a 620-nm reference
was measured in an ELISA plate reader. The intensity of the staining is proportional to the
concentration of IgG (IgM) to SARS-CoV-2 in the analyzed sample. The total procedure
requires 10 µL of plasma and the duration of the assay is about 2 h.
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The sensitivity of the SARS-Cov-2-IgG-EIA-BEST is 71.6% during the initial stages
of antibody production and 100% in later stages; the sensitivity of SARS-Cov-2-IgM-
EIA-BEST is 82% and 95.4%, respectively [29]. The specificity of the test system used is
99.72–99.93% [29].
2.5. Adjusting Prevalence Estimates
The adjusted prevalence was estimated using the following formula according to
Sempos and Tian [30]. The adjusted prevalence was calculated to avoid the test kit errors
and to harmonize results over time and place [30].
adjusted prevalence =
crude prevalence + specificity − 1
sensitivity + specificity − 1 (1)
2.6. Positivity Coefficient (CP) Calculations
Positivity coefficient (CP) calculations to display the antibody content were carried
out following the manufacturer’s instructions [31]. CP shows how many times the concen-
tration of antibodies exceeds the threshold value.
For this, the arithmetic mean values of optical density in the wells with a negative
control sample (ODaverage. K−) were calculated. The results were accounted for if the
following conditions were met—the average OD value in the well with K was not more
than 0.2—OD value in the well with K+ was not less than 0.5.
On the next step, the critical value of optical density (ODcrit.) was calculated by
the formula:
ODcritical = ODaverageK + 0.2. (2)
CP was calculated using the formula:
CP = ODsample/ODcritical (3)
where ODsample is the OD value in a well with control or analyzed sample.
The test results were considered positive if CP was equal or more than 1.1, negative—if
CP was less than 0.8, doubtful—if the results were between 0.8 and 1.1.
2.7. Statistical Analysis
Data management and analysis were carried out using software R 3.1.1 12 (R Foun-
dation for Statistical Computing, Vienna, Austria) and Microsoft Excel version 14.0. Since
all selected groups of the general sample had an abnormal distribution (Shapiro–Wilk
test < 0.05), the statistical criteria chosen for the calculations were nonparametric. To study
the correlation between the age of patients and the concentration of immunoglobulins, the
Spearman rank test was chosen. The Kruskal–Wallis rank test was used to compare the
concentration of immunoglobulins between men and women and between individuals
from the “high-risk” and “symptomatic” groups.
3. Results
Samples from 1101 men and 682 women with an average age of 39 years were investi-
gated (Table 1). Of the 1091 persons who composed the “high-risk” group, 310 (28.41%)
were women with an average age of 47.79 years and 781 (71.59%) were men (average age
39.91 years). Additionally, 372 (53.76%) women with an average age of 41.39 years and 320
(46.24%) men (average age 39.67 years) comprised the “symptomatic” group.
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Table 1. Demographic characteristics of the study participants.
Risk Group Gender Count Prevalence withinthe Group Prevalence Mean Age
High-risk Men 781 72% 44% 36.91
Women 310 28% 17% 41.79
Symptomatic Men 320 46% 18% 39.67
Women 372 54% 21% 41.39
Blood samples were tested for the presence of both IgM and IgG with the above-
mentioned ELISA kits. The detailed distribution of the seropositivity rates is presented in
Table 2.
Table 2. Seropositivity rates for joint detection of IgG and IgM in persons of high-risk and symp-
tomatic groups.






1 IgM [−] and IgG [−] women 423 62.02% 23.72%men 839 76.20% 47.06%
2 IgM [−] and IgG [+] women 41 6.01% 2.30%men 44 4.00% 2.47%
3 IgM [−] and IgG [*] women 3 0.44% 0.17%men 3 0.27% 0.17%
4 IgM [+] and IgG [−] women 21 3.08% 1.18%men 25 2.27% 1.40%
5 IgM [+] and IgG [+]
women 165 24.19% 9.25%
men 170 15.44% 9.53%
6 IgM [+] and IgG [*]
women 8 1.17% 0.45%
men 3 0.27% 0.17%
7 IgM [*] and IgG [−] women 2 0.29% 0.11%men 7 0.64% 0.39%
8 IgM [*] and IgG [+]
women 19 2.79% 1.07%
men 10 0.91% 0.56%
High−risk vs. Symptomatic
1 IgM [−] and IgG [−] high−risk 895 82.03% 50.20%symptomatic 367 53.03% 20.58%
2 IgM [−] and IgG [+] high−risk 45 4.12% 2.52%symptomatic 40 5.78% 2.24%
3 IgM [−] and IgG [*] high−risk 3 0.27% 0.17%symptomatic 3 0.43% 0.17%
4 IgM [+] and IgG [−] high−risk 21 1.92% 1.18%symptomatic 25 3.61% 1.40%
5 IgM [+] and IgG [+]
high−risk 113 10.36% 6.34%
symptomatic 222 32.08% 12.45%
6 IgM [+] and IgG [*]
high−risk 5 0.46% 0.28%
symptomatic 6 0.87% 0.34%
7 IgM [*] and IgG [−] high−risk 5 0.46% 0.28%symptomatic 4 0.58% 0.22%
8 IgM [*] and IgG [+]
high−risk 4 0.37% 0.22%
symptomatic 25 3.61% 1.40%
Note: [+]—positive results; [−]—negative results; [*]—doubtful results. The overall seropositivity was a calculated
sum of variants [2 + 8] (IgG)/[4 − 6] (IgM)/[5] (IgM + IgG).
3.1. Seropositivity Rates for Joint Detection of IgG and IgM in Persons of High-Risk and
Symptomatic Groups
Among the 1091 persons from the “high-risk” group, positive results for the presence
of SARS-CoV-2 antibodies were detected in 17.23% of cases (IgG was detected in 4.49%,
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IgM—in 2.38%, both IgG and IgM—in 10.36% of cases), doubtful results—in 0.73% of cases
(Table 2).
Among the 692 persons from the “symptomatic” group, positive results for the pres-
ence of SARS-CoV-2 antibodies were detected in 45.95% of cases (IgG was detected in
9.39%, IgM—in 4.48%, both IgG and IgM—in 32.08% of cases), doubtful results—in 1.01%
of cases.
The crude seropositivity rate in the total sample was 28.38% (IgG were detected in
6.4%, IgM—in 3.2%, both IgG and IgM—in 18.78% of cases); doubtful results were obtained
in 0.84% (Table 2). With that, the crude seroprevalence of SARS-CoV-2 antibodies was
significantly higher in women (37.4%) than in men (22.89%). Thus, IgG were detected in
32.99% of women and 20.35% of men, IgM—in 28.45% of women and 17.98% of men, both
IgG and IgM—in 24.19% of women and 15.44 of men.
3.2. Adjusted Seropositivity Rates for Joint Detection of IgG and IgM in Persons of High-Risk and
Symptomatic Groups
The measurement errors of tests can result in biased prevalence estimates, and thus,
the adjusted seropositivity rates were calculated [30] depending on the possible stage of
infection when the samples were taken (early stages of infection, when the sensitivity of the
tests was low, or the peak of infection, when sensitivity of the tests reached 100%) (Table 3).




6–12 Days * 13–20 Days *
Adj. Prev. Cr. Prev. Adj. Count Adj. Prev. Cr. Prev. Adj. Count
IgM and IgG positive
All patients 18.87% 18.79% 336 18.73% 18.79% 334
Women 24.31% 24.19% 166 24.14% 24.19% 165
Men 15.49% 15.44% 171 15.38% 15.44% 169
High-risk 10.37% 10.36% 113 10.29% 10.36% 113
Symptomatic 32.26% 32.08% 223 32.03% 32.08% 218
IgG positive
All patients 8.61% 6.39% 153 6.16% 6.39% 110
Women 11.98% 8.80% 82 8.57% 8.80% 58
Men 6.52% 4.90% 72 4.66% 4.90% 51
High-risk 5.94% 4.49% 65 4.25% 4.49% 47
Symptomatic 12.81% 9.39% 89 9.17% 9.39% 63
IgM positive
All patients 3.57% 3.20% 64 3.07% 3.20% 55
Women 4.86% 4.25% 33 4.17% 4.25% 28
Men 2.77% 2.54% 30 2.38% 2.54% 26
High-risk 2.57% 2.38% 28 2.21% 2.38% 24
Symptomatic 5.14% 4.48% 36 4.42% 4.48% 30
Note: *—from the possible 1st day of the disease; Cr. Prev.—crude prevalence; Adj. prev.—adjusted prevalence [30].
According to the conducted calculations, the adjusted seropositivity in the total sample
was 28.33–28.53% (for IgG-positive, 6.16–8.61%; for IgM-positive, 3.07–3.57%; both IgG and
IgM-positive—18.73–18.87%).
Adjusted seropositivity was significantly higher in the “symptomatic” group—45.91–46.24%
compared to the values (17.17–17.29%) of the “high-risk” group. Seropositivity for two
immunoglobulins (the presence of IgM and IgG to SARS-CoV-2) was 10.29–10.37% in the
“high-risk” group and 32.03–32.26% in the “symptomatic” group. Seropositivity of individ-
ual IgM-positive and IgG-positive patients from the “high-risk” group was 2.21–2.57% and
4.25–5.94%, respectively. For the “symptomatic” group, a similar calculation of seropositiv-
ity revealed the higher values: 9.17–12.81% for IgG-positive and 4.42–5.14% for IgM.
Adjusted seroprevalence of antibodies to SARS-CoV-2 in women was 45.91–46.24%
(for IgG-positive, 8.57–11.98%; for IgM-positive, 4.17–4.86%; both IgG and IgM-positive—
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24.14–24.31%) and in men 17.17–17.29% (for IgG-positive, 4.66–6.52%; for IgM-positive,
2.38–2.77%; both IgG and IgM-positive—15.38–15.49%).
3.3. Antibody Content
The average content of IgM antibodies in the total sample was 1.59, and the average
content of IgG was 3.17.
According to the Spearmen test, the statistically significant positive relationship was
found between age and IgM levels (S = 852,570,000, rho = 0.084, p-value = 0.0004) and
between age and IgG levels (S = 860,350,000, rho = 0.075, p-value = 0.015). A statisti-
cally significant positive relationship was also found between the IgG and IgM levels
(S = 328,150,000, rho = 0.65, p-value < 0.0001).
According to the analysis, the bimodal distribution of IgM and IgG content with two
peaks on both sides of the boundaries of the reference interval among men and women
and persons from the symptomatic and high-risk groups (Figure 1) was present.
Figure 1. Distribution of IgM and IgG content with two peaks on both sides of the boundaries of the reference interval
among persons from the symptomatic and high-risk groups and men and women.
According to the Mann–Whitney test, the higher IgG and IgM levels were observed
in women compared with men (for IgM-Mann–Whitney U-test = 3.476, p-value = 0.0005,
ES = 0.11, Power = 0.37, Sample size = 4502; for IgG-Mann–Whitney U-test = −5.586,
p-value ≤ 0.0001, ES = 0.33, Power = 0.99, Sample size = 502) and subjects from the
symptomatic group compared with those from the high-risk group (for IgM-Mann–Whitney
U-test = 8.490, p-value < 0.0001, ES = 0.46, Power = 0.99, Sample size = 260; for IgG-Mann–
Whitney U-test = 11.975, p-value < 0.0001, ES = 0.44, Power = 0.99, Sample size = 284).
4. Discussion
COVID-19 is currently the top public health concern worldwide. It is estimated that
approximately 97% of the world’s population is susceptible to SARS-CoV-2 [14]. Previous
studies have indicated that the overall seroprevalence varies widely across different coun-
tries and regions, with a higher seropositivity prevalence being observed in locations of
early outbreaks, as well as countries with higher income levels and human development
index scores [10,32,33].
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During the pandemic, the assessment of IgM and IgG has been used to diagnose
COVID-19, allowing the evaluation of not only the cumulative prevalence of SARS-CoV-2
infection but also the monitoring of seroconversion at the individual and community
levels [32,34]. The overall seropositivity estimate in the present study (28.33–28.53%) is
similar to that reported from the general population of the Ural Federal District of Russia
(24.5–31.3%), which comprises six federal districts: the Tyumen Region, Chelyabinsk Oblast,
and Republic of Tatarstan [25,26]. However, our observed seroprevalence is significantly
higher than the earlier estimate of 9–10.8% from May to June [24]; this reflects the gradual
development of herd immunity and that SARS-CoV-2 continues to spread through the pop-
ulation, resulting in more symptomatic infections and, thus, more seropositive individuals.
The present study was conducted among persons in occupations with a high risk of
exposure to SARS-CoV-2 [35]. It is considered that these persons experience a potentially
higher SARS-CoV-2 exposure risk due to the nature of their job than the general popula-
tion [10,20,21]. Thus, according to the study of F-Y Lan et al. (2020), employees with direct
customer exposure were five times more likely to test positive for SARS-CoV-2 [18], while
the seroprevalence of COVID-19 amongst police officers was at least 3.4 higher than in the
general population [36]. Nevertheless, some recent data suggest that the seroprevalence of
SARS-CoV-2 antibodies in persons from high-risk groups is similar [3] or only marginally
higher [10,37] compared to that in the general population, depending on regional variation
in COVID-19 incidence. Based on this, we initially assumed that the seroprevalence levels
in the high-risk group would be near the upper limit of the general population. However,
SARS-CoV-2 antibodies were only detected in 28.38% (adjusted prevalence 28.33–28.53%)
of cases, which is significantly lower than the seroprevalence of the general population in
neighboring regions [26,27]. The lower seroprevalence may be attributed to greater avail-
ability and enforcement of healthcare protocols, as well as the use of adequate personal
protective equipment.
The prevalence (45.95%) and levels of SARS-CoV-2 antibodies in participants from
the symptomatic group were significantly higher than those in the high-risk group. These
results match other studies [16] and are similar to those reported by Naaber et al. (2020),
who found that the positivity rate in asymptomatic COVID-19 cases was approximately
two times lower compared to polysymptomatic cases; furthermore, patients with more
symptoms usually had a higher positivity rate and antibody level [38].
Existing evidence suggests that seroprevalence worldwide is equivalent between
sexes [10,17]. Moreover, according to the recent study of C Luo et al. (2021), SARS-CoV-2
IgG/IgM dynamic is mainly affected by age and disease severity, not sex [16]. However, the
present study found a higher seroprevalence in women (37.4%) than in men (17.17–22.89%);
these values are similar to those reported from neighboring regions of Russia [25,26].
There are several possible explanations for this result. This may be attributable to many
factors, including similar age and sex distributions, employment structures, and/or cultural
practices in Russia. Although, this finding may be explained by the fact that the decline
positive rate of IgG/IgM antibodies is lower and the average titer of IgG/IgM antibodies is
relatively higher in females from disease onset to 60 days [16,39].
Thus, consistent with the literature, this research found that antibody levels were higher
in women compared to men, as well as in older versus younger participants [16,37,39,40].
Data from several studies suggest that the immune response to most pathogen vaccines in
men is lower than that in women [41,42]. Estrogen and testosterone promote and suppress,
respectively, the innate and adaptive immune systems [40]. Within the innate immune
system, estrogen regulates innate myeloid (monocytes, dendric cells, neutrophils) and
lymphoid cells and promotes type I IFN synthesis [43,44]. In turn, within the adaptive
immune system, the higher numbers of CD4+ Helper T cells, more robust CD8+ (cytotoxic)
T cells cytotoxic activity, and higher B cell production of immunoglobulin are observed in
women compared to men [45]. Thus, women have an increased capacity to mount greater
magnitudes of immune responses against the infection compared to men [45], and that
may underlie the different outcomes between sexes [39,46].
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However, the contemporary clinical data are rather controversial, and there is no
general agreement about the impact of sex on antibody generation and prognosis in
SARS-CoV-2 infection [16,47–52]. While several studies have reported higher levels of
antibodies in women [39,48], other studies have reported equivalent levels between men
and women [16,39], as well as higher levels in men [40,49–51]. Thus, further research
should be undertaken to investigate the impact of sex and gender on immune response
and associated adverse COVID-19 outcomes and to tailor the potential treatment according
to sex and gender [45,51,52].
The obtained results are in accord with recent studies indicating that average IgG/IgM
antibody levels were higher in old ages [16,53]. These results are likely to be related to an
increased baseline level of proinflammatory cytokines associated with such comorbidities
as obesity, hypertension, or diabetes, which are common in the elderly and could have a
stimulatory effect on the SARS-CoV-2 humoral response [53,54].
5. Conclusions
The herd immunity threshold for SARS-CoV-2 is approximately 67% [55]. The results
of this study indicate that the seroprevalence in Russia is relatively low and inadequate for
herd immunity. Therefore, we emphasize the importance of maintaining current public
health measures and intensifying vaccination efforts to keep the outbreak under control.
This study had several limitations due to the scale of the COVID-19 pandemic. First,
this study was limited to a single city. Therefore, the results may not be generalizable to
other regions that are more geographically diverse. Furthermore, due to the regulation
rules, persons aged >65 years were not permitted to work during the pandemic; this
may have affected the seropositivity rates observed in this study. Second, as random
sampling was not used, the estimated seroprevalence was subject to potential sampling
bias. Third, samples collected from infected individuals outside the antibody response time
window and low diagnostic rates of the used commercial test systems in the initial phase
of infection may have yielded false-negative results; therefore, the observed seroprevalence
in our study may have underestimated the true prevalence rate of COVID-19. Fourth, we
did not evaluate dynamic changes in antibody titers in infected individuals over time,
and depending on the sampling time, there might be a higher incidence of seropositive
individuals in the symptomatic group. Fifth, the prevalence estimates may change with
new information on the accuracy of the test kits that we used. Sixth, since the majority
of COVID-19 patients are either asymptomatic or have only a few mild symptoms, the
sensitivity of the antibody tests in the general population may be lower; this may affect the
reliability of antibody-based epidemiological studies [20].
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